Affiliation:
1. Department of Health Research Methods, Evidence, and Impact McMaster University Hamilton Ontario Canada
2. Department of Medicine McMaster University Hamilton Ontario Canada
3. Keele Cardiovascular Research Group Keele University Stroke‐on‐Trent United Kingdom
4. Population Health Research Institute Hamilton Ontario Canada
Abstract
Background
Patient‐reported outcomes (PROs) are important measures of treatment response in heart failure. We assessed temporal trends in and factors associated with inclusion of PROs in heart failure randomized controlled trials (RCTs).
Methods and Results
We searched MEDLINE, Embase, and CINAHL for studies published between January 2000 and July 2020 in journals with an impact factor ≥10. We assessed temporal trends using the Jonckheere‐Terpstra test and conducted multivariable logistic regression to explore trial characteristics associated with PRO inclusion. We assessed the quality of PRO reporting using the Consolidated Standards of Reporting Trials (CONSORT) PRO extension. Of 417 RCTs included, PROs were reported in 226 (54.2%; 95% CI, 49.3%–59.1%), with increased reporting between 2000 and 2020 (
P
<0.001). The odds of PRO inclusion were greater in RCTs that were published in recent years (adjusted odds ratio [aOR] per year, 1.08; 95% CI, 1.04–1.12;
P
<0.001), multicenter (aOR, 1.89; 95% CI, 1.03–3.46;
P
=0.040), medium‐sized (aOR, 2.35; 95% CI, 1.26–4.40;
P
=0.008), coordinated in Central and South America (aOR, 5.93; 95% CI, 1.14–30.97;
P
=0.035), and tested health service (aOR, 3.12; 95% CI, 1.49–6.55;
P
=0.003), device/surgical (aOR, 6.66; 95% CI, 3.15–14.05;
P
<0.001), or exercise (aOR, 4.66; 95% CI, 1.81–12.00;
P
=0.001) interventions. RCTs reported a median of 4 (interquartile interval , 3–6) of a possible of 11 CONSORT PRO items.
Conclusions
Just over half of all heart failure RCTs published in high impact factor journals between 2000 and 2020 included PROs, with increased inclusion of PROs over time. Trials that were large, tested pharmaceutical interventions, and coordinated in North America / Europe had lower adjusted odds of reporting PROs relative to other trials. The quality of PRO reporting was modest.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Reference49 articles.
1. US Department of Health and Human Services Food and Drug Administration Guidance for industry: patient‐reported outcome measures use in medical product development to support labeling claims. Available at: https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/patient‐reported‐outcome‐measures‐use‐medical‐product‐development‐support‐labeling‐claims. Accessed October 21 2020.
2. Canadian Institute of Health Information: Patient‐Reported Outcome Measures (PROMs). Available at: https://www.cihi.ca/en/patient‐reported‐outcome‐measures‐proms. Accessed October 21 2020.
3. Cardiovascular Health: The Importance of Measuring Patient-Reported Health Status
4. The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials
5. Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献